Cerebrovascular Diseases
Original Paper
Pituitary Function and IGF-I Levels following Ischemic StrokeBoehncke S.a · Ackermann H.b · Badenhoop K.a · Sitzer M.caDepartment of Internal Medicine 1, Division of Endocrinology, Diabetes and Metabolism, bDepartment of Biostatistics, and cDepartment of Neurology, Stroke Unit, J.W. Goethe University, Frankfurt/M., Germany
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 03, 2010
Accepted: September 29, 2010
Published online: December 04, 2010
Issue release date: January 2011
Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 6
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Abstract
Background: Pituitary dysfunction is a known complication of traumatic brain injury and subarachnoidal hemorrhage but there are few data about pituitary dysfunction as a complication of ischemic stroke. Methods: We prospectively studied patients 66–274 days after an ischemic stroke, evaluating the prevalence of pituitary dysfunction (by combined releasing hormone testing: GHRH, CRH), stroke severity, outcome and incidence of anxiety and depression. Results: Thirty-two patients (82%) presented with some degree of pituitary dysfunction with predominantly impaired growth hormone response (79.5%) and secondary adrenal failure (14.6%). Abnormal anxiety and/or depression was found in 28.3 and 32.7% of the patients. NIHSS (National Institute of Health Stroke Scale) varied between 1 and 15. Improvement in neurological deficit (ΔNIHSS) correlated significantly with NIHSS at baseline (p < 0.001) but not with pituitary function. Conclusions: Patients with ischemic stroke may suffer from pituitary dysfunction with predominantly impaired growth hormone response and secondary adrenal failure. We suggest that patients who suffer from stroke should undergo pituitary testing.
© 2010 S. Karger AG, Basel
Related Articles:
References
- Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747–1757.
- Ferro JM, Caeiro L, Santos C: Poststroke emotional and behavior impairment: a narrative review. Cerebrovasc Dis 2009;27(suppl 1):197–203.
- Wallymahmed ME, Foy P, Mac Farlane IA: The quality of life of adults with growth hormone deficiency: a comparison with diabetic patients and control subjects. Clin Endocrinol 1999;51:333–338.
- Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, Stalla GK, Agha A: Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 2007;298:1429–1438.
- Van Rijn MJ, Slooter AJ, Bos MJ, Catarino CF, Koudstaal PJ, Hofman A, Breteler MM, van Duijn CM: Insulin-like growth factor I promoter polymorphism, risk of stroke, and survival after stroke: the Rotterdam Study. J Neurol Neurosurg Psychiatry 2006;77:24–27.
- Bondanelli M, Ambrosio MR, Onofri A, Bergonzoni A, Lavezzi S, Zatelli MC, Valle D, Basaglia N, degli Uberti EC: Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2006;91:3928–3934.
- European Stroke Initiative Executive Committee and the EUSI Writing Committee: European Stroke Initiative Recommendations for Stroke Management – Update 2003. Cerebrovasc Dis 2003;16:311–337.
- Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, Zivin J, NINDS tPA Stroke Trial Investigators: Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. Stroke 1999;30:2347–2354.
- Banks JL, Marotta CA: Outcomes validity and reliability of the Modified Rankin Scale: implications for stroke clinical trials – A literature review and synthesis. Stroke 2007;38:1091–1096.
- Mahoney FI, Barthel D: Functional evaluation: the Barthel Index. Maryland State Med J 1965;14:56–61.
-
Zigmond A, Snaith R: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–370.
External Resources
-
Allolio B, Schulte HM: Praktische Endokrinologie. München, Urban & Schwarzenberg,1996, pp 219–227.
- Johansson P, Olsson T, Carlberg B, Karlsson K, Fagerlund M: Hypercortisolism after stroke – partly cytokine-mediated? J Neurol Sci 1997;147:43–47.
- Astrom M, Olsson T, Asplund K: Different linkage of depression to hypercortisolism early versus late after stroke: a 3-year longitudinal study. Stroke 1993;24:52–57.
- Weber-Hamann B, Blum WF, Kratzsch J, Gilles M, Heuser I, Deuschle M: Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009;42:23–28.
- Deuschle M, Blum WF, Strasburger CJ, Schweiger U, Weber B, Korner A, Standhardt H, Gotthardt U, Schmider J, Pflaum CD, Heuser I: Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology 1997;22:493–503.
- Arwert LI, Deijen JB, Müller M, Drent ML: Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav 2005;47:343–349.
- Tanriverdi F, Dagli AT, Karaca Z, Unluhizarci K, Selcuklu A, Casanueva FF, Kelestimur F: High risk of pituitary dysfunction due to aneurysmal subarachnoid haemorrhage: a prospective investigation of anterior pituitary function in the acute phase and 12 months after the event. Clin Endocrinol 2007;67:931–937.
- Kooijman R, Sarre S, Michotte Y, De Keyser J: Insulin-like growth factor I: a potential neuroprotective compound for the treatment of acute ischemic stroke? Stroke 2009;40:e83–e88.
- Denti L, Annoni V, Cattadori E, Salvagnini MA, Visioli S, Merli MF, Corradi F, Ceresini G, Valenti G, Hoffman AR, Ceda GP: Insulin-like growth factor 1 as a predictor of ischemic stroke outcome in the elderly. Am J Med 2004;117:312–317.
- Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK, Ghigo E: Hypopituitarism. Lancet 2007;369:1461–1470.
- Reschke K, Pfeiffer AF, Lehnert H: Hormone replacement therapy. What is reliable? Internist 2003;44:98–109.
- Adams HP, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR, Woolson RF, Hansen MD: Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 1999;53:126–131.
- Appelros P, Terént A: Characteristics of the National Institute of Health Stroke Scale: results from a population-based stroke cohort at baseline and after one year. Cerebrovasc Dis 2004;17:21–27.
Article / Publication Details
Received: May 03, 2010
Accepted: September 29, 2010
Published online: December 04, 2010
Issue release date: January 2011
Number of Print Pages: 7
Number of Figures: 4
Number of Tables: 6
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
